Edwards Lifesciences Corp Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/2/2026)
| Balance Sheet | Total Assets | 13,697,200,000.00 | ROE | 75.47 % |
| Balance Sheet | Total Equity | 10,337,600,000.00 | ROA | 7.84 % |
| Cashflow | Capital Expenditures | -260,200,000.00 | P/FCF | 37.62 |
| Cashflow | Free Cash Flow | 1,335,000,064.00 | – | – |
| Cashflow | Operating Cash Flow | 1,595,200,000.00 | P/CF | 31.49 |
| Income | Earnings per Share (diluted) | 1.83 | Div. Yield | – |
| Income | Net Income | 1,073,500,000.00 | P/E | 47.24 |
| Income | Shares Outstanding | 581,000,000.00 | P/B | 4.86 |
| Income | Total Revenue | 6,067,600,000.00 | P/S | 8.28 |
Ratios calculated on: 10/14/2026
Company Description
Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.edwards.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more